Recently, M3258 was synthesized using the α-aminoboronic acid scaffold as a starting point to optimize selectivity for PSMB8 (> 500fold over PSMB5) and has entered early clinical trials for multiple myeloma [14, 36, 37]. The gene discussed is PSMB8; the disease is plasma cell myeloma.